Glaukos Corp (N:GKOS)

Business Focus: Medical Devices & Implants

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
See Regulatory Filings on SEC
Company Contact
Address: 229 Avenida Fabricante
SAN CLEMENTE CA 92672-7531
Tel: N/A
IR: See website
Key People
William J. Link
Independent Chairman of the Board
Thomas William Burns
President, Chief Executive Officer and Director
Joseph E. Gilliam
Chief Financial Officer, Senior Vice President - Corporate Development
Chris M. Calcaterra
Chief Operating Officer
L. Jay Katz
Chief Medical Officer
Business Overview
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.
Financial Overview
For the three months ended 31 March 2019, Glaukos Corp revenues increased 35% to $54M. Net loss decreased 50% to $1.3M. Revenues reflect United States segment increase of 32% to $44.2M, International segment increase of 50% to $9.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.08 to -$0.04.
Employees: 437 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $2,606M as of Mar 31, 2019
Annual revenue (TTM): $195.17M as of Mar 31, 2019
EBITDA (TTM): -$5.39M as of Mar 31, 2019
Net annual income (TTM): -$11.58M as of Mar 31, 2019
Free cash flow (TTM): $15.80M as of Mar 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 36,402,966 as of May 6, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization